Patent US3926402A successfully refreshed from Google Patents.
Patent US4696949A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4696949A Expired / Lapsed US ⏱️ 0.0 years remaining

Novel tri-phenyl alkane and alkene derivatives and their preparation and use

Assignee: Orion Oyj
•
Filing: 1986-01-29
•
Granted: 1987-09-29
•
Expires: 2006-01-29
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention provides novel compounds of the formula: ##STR1## wherein n is 0 to 4, R 1 and R 2 , which can be the same or different are H, OH, alkoxy of 1 to 4 carbon atoms, benzyloxy or methoxymethoxy; R 3 is H, OH, halogen, alkoxy of 1 to 4 carbon atoms, benzyloxy, methoxymethoxy, 2,3-dihydroxypropoxy or ##STR2## wherein m is 1 or 2, R 6 and R 7 , which can be the same or different are H or an alkyl group of 1 to 4 carbon atoms, or ##STR3## can form an N-containing three-, four-, five- or six-membered heterocyclic ring; R 4 is OH, F, Cl, Br, I, mesyloxy, tosyloxy, alkylcarbonyloxy of 1 to 4 C-atoms, formyloxy or CH 2 R 4 is replaced by CHO; R 5 is H or OH; or R 4 and R 5 together form an --O-- bridge between the carbon atoms to which they are attached, and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof. Processes for the preparation of these compounds are described, and also novel pharmaceutical compositions containing them. These compounds exhibit valuable pharmacological properties as estrogenic, anti-estrogenic, and progestanic agents. They are also effective against oestrogen-dependent tumors. Certain compounds are useful as chemical intermediates for the preparation of pharmacologically active compounds of the invention.

Inventors

  • 👤 Reijo J. Toivola
  • 👤 Arto J. Karjalainen
  • 👤 Kauko O. A. Kurkela
  • 👤 Marja-Liisa Soderwall
  • 👤 Lauri V. M. Kangas
  • 👤 Guillermo L. Blanco
  • 👤 Hannu K. Sunduiqst

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 19:34
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/04; C07D295/08; C07D295/084; C07D295/088; C07C; C07C29/00; C07C29/09; C07C29/095; C07C29/10; C07C29/128; C07C29/1285; C07C309/00; C07C33/00; C07C33/26; C07C33/28; C07C37/00; C07C37/001; C07C37/01; C07C37/055; C07C39/00; C07C39/12; C07C39/205; C07C39/21; C07C39/24; C07C39/367; C07C39/373; C07C43/00; C07C43/02; C07C43/03; C07C43/14; C07C43/178; C07C43/1782; C07C43/20; C07C43/225; C07C43/23; C07D307/00; C07D307/02; C07D307/04; C07D307/06; C07D307/10; C07D307/12; C07D307/14; C07D309/00; C07D309/02; C07D309/04; C07D309/08; C07D309/10; C07D309/12

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 15 words
A compound of the formula: ##STR50## or a non-toxic pharmaceutically acceptable salt or N-oxides thereof.
Claim 2
Dependent Claim 15 words
A compound of the formula: ##STR50## or a non-toxic pharmaceutically acceptable salt or N-oxides thereof.
Claim 3
Dependent Claim 16 words
A compound according to claim 1 which is 4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene or a non-toxic pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim 19 words
A compound according to claim 1 which is the trans-isomer of 4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene or a non-toxic pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim 15 words
A compound according to claim 1 which is the citrate of the trans-isomer of 4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene.
Claim 6
Dependent Claim 32 words
A pharmaceutical composition suitable for treating hormone-dependent tumours comprising an anti-tumour effective amount of a compound of claim 1 or a non-toxic pharmaceutically acceptable salt thereof and a compatible pharmaceutically carrier therefor.
Claim 7
Dependent Claim 42 words
A method of producing an anti-oestrogenic effect in a subject in which such an effect is desired which comprises administering to said subject an anti-oestrogenic effective amount of a compound as defined in claim 3 or a non-toxic pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim 21 words
A method according to claim 6 in which an antioestrogenic effect is produced in a subject suffering from an oestrogen-dependent tumour.

References Cited (Backward Citations)

GB1015787A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-09-28 1991-03-30 1991-09-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-09-28 1995-03-30 1995-09-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-09-28 1999-03-30 1999-09-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag